Uncoupling of osteoblast-osteoclast regulation in a chemical murine model of gaucher disease

Gene

Volumn 532, Issue 2, 2013, Pages 186-191

  Mucci, Juan M ^a   Suqueli García, Florencia ^a   de Francesco, Pablo N ^a   Ceci, Romina ^a   Di Genaro, S ^b   Fossati, Carlos A ^a   Delpino, M Victoria ^c   Rozenfeld, Paula A ^a  

^a FACULTAD DE CIENCIAS EXACTAS   (Argentina)

^b UNIVERSIDAD NACIONAL DE SAN LUIS   (Argentina)

^c HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

Author keywords

Bone disease; Gaucher disease; Glucocerebrosidase deficiency; Macrophages; Pathophysiology; TNF

Indexed keywords

ALKALINE PHOSPHATASE; EPOXIDE; GLUCOSYLCERAMIDASE; GLYCOSIDASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; VITRONECTIN RECEPTOR;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MINERALIZATION; CELL CULTURE; CELL GROWTH; CELL ISOLATION; CELL LINEAGE; CELL MATURATION; CONTROLLED STUDY; CULTURE MEDIUM; FEMALE; GAUCHER DISEASE; HEMATOPOIETIC STEM CELL; IN VITRO STUDY; MACROPHAGE; MONOCYTE; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL;

Α-MEM; Α-MINIMUM ESSENTIAL MEDIUM; ALIZARIN RED S; ARS; BONE DISEASE; CBE; CELL SURFACE RECEPTOR OF TNF-Α; CM; CONDITIONED MEDIA; CONDURITOL-BETA-EPOXIDE; GAUCHER DISEASE; GBA; GCASE; GD; GLUCOCEREBROSIDASE; GLUCOCEREBROSIDASE DEFICIENCY; GLUCOCEREBROSIDASE GENE; KNOCK OUT MICE FOR CELL SURFACE RECEPTOR OF TNF-Α; M-CSF; MACROPHAGE COLONY STIMULATING FACTOR; MACROPHAGES; MATRIX METALLOPROTEINASES; MC3T3; MMP; MURINE OSTEOBLASTS CELL LINE; PATHOPHYSIOLOGY; PERITONEAL MACROPHAGES; PM; RANKL; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA-B LIGAND; S; SDS; SODIUM DODECYL SULFATE; SPLENOCYTES; TARTRATE-RESISTANT ACID PHOSPHATASE; TNF-Α; TNFRKO; TNFRP55; TRAP; TUMOR NECROSIS FACTOR ALPHA;

ANIMALS; ANTIGENS, DIFFERENTIATION; BONE MARROW CELLS; CALCIFICATION, PHYSIOLOGIC; CELL DIFFERENTIATION; CELLS, CULTURED; CULTURE MEDIA, CONDITIONED; GAUCHER DISEASE; INOSITOL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OSTEOBLASTS; OSTEOCLASTS; OSTEOLYSIS; TUMOR NECROSIS FACTOR-ALPHA;

MURINAE; MUS;

EID: 84886750765     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2013.09.072     Document Type: Article

References (12)

1. Beutler E. Treatment regimens in Gaucher's disease. Lancet 1995, 346(8974):581-582. (Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/7658807).
2. Ciana G., et al. Gaucher disease and bone: laboratory and skeletal mineral density variations during a long period of enzyme replacement therapy. J. Inherit. Metab. Dis. 2005, 28(5):723-732. 10.1007/s10545-005-0032-y.
3. Cox T.M. Gaucher disease: clinical profile and therapeutic developments. Biologics 2010, 4:299-313. 10.2147/BTT.S7582.
4. Deegan P.B., et al. Osseous manifestations of adult Gaucher disease in the era of enzyme replacement therapy. Medicine 2011, 90(1):52-60. 10.1097/MD.0b013e3182057be4.
5. Giambartolomei G.H., Zwerdling A., Cassataro J., Bruno L., Fossati C.A., Philipp M.T. Lipoproteins, not lipopolysaccharide, are the key mediators of the proinflammatory response elicited by heat-killed Brucella abortus. J. Immunol. 2004, 173(7):4635-4642. (Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/15383598).
6. Lecourt S., et al. Bone marrow microenvironment in an in vitro model of Gaucher disease: consequences of glucocerebrosidase deficiency. Stem Cells Dev. 2011, 1-33. 10.1089/scd.2011.0365.
7. Mistry P.K., et al. Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage. Proc. Natl. Acad. Sci. U. S. A. 2010, 107(45):19473-19478. 10.1073/pnas.1003308107.
8. Mucci J.M., et al. Induction of osteoclastogenesis in an in vitro model of Gaucher disease is mediated by T cells via TNF-α. Gene 2012, 509(1):51-59. 10.1016/j.gene.2012.07.071.
9. Reed M., Baker R.J., Mehta A.B., Hughes D.A. Enhanced differentiation of osteoclasts from mononuclear precursors in patients with Gaucher disease. Blood Cells Mol. Dis. 2013, 51(3):185-194. 10.1016/j.bcmd.2013.04.006.
10. Sims K.B., et al. Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study. Clin. Genet. 2008, 73(5):430-440. 10.1111/j.1399-0004.2008.00978.x.
11. Stirnemann J., Belmatoug N., Vincent C., Fain O., Fantin B., Mentré F. Bone events and evolution of biologic markers in Gaucher disease before and during treatment. Arthritis Res. Ther. 2010, 12(4):R156. 10.1186/ar3111.
12. Wenstrup R.J., Roca-Espiau M., Weinreb N.J., Bembi B. Skeletal aspects of Gaucher disease: a review. Br. J. Radiol. 2002, 75(Suppl. 1):A2-A12. (Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/12036828).